Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas.

Publication

Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas.

Journal Paper/Review - Sep 28, 2022

Weber Lorenz, Padevit Luis, Müller Timothy, Velz Julia, Vasella Flavio, Voglis Stefanos, Gramatzki Dorothee, Weller Michael, Regli Luca, Sarnthein Johannes, Neidert Marian Christoph

Citation

Weber L, Padevit L, Müller T, Velz J, Vasella F, Voglis S, Gramatzki D, Weller M, Regli L, Sarnthein J, Neidert M. Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas. Front Oncol 2022; 12:959072.

Type

Journal Paper/Review (English)

Journal

Front Oncol 2022; 12

Publication Date

Sep 28, 2022

Issn Print

2234-943X

Pages

959072

Brief description/objective

Maximum safe resection followed by chemoradiotherapy as current standard of care for WHO grade III and IV gliomas can be influenced by the occurrence of perioperative adverse events (AE). The aim of this study was to determine the association of AE with the timing and choice of subsequent treatments as well as with overall survival (OS).